🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "major milestone" in the fight against drug-resistant strains of the pathogen, according to health experts.

An International Public Health Issue

Gonorrhoea infections are on the rise globally, with data suggesting over 82 million instances annually. Especially elevated rates are reported in Africa and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary step in the face of growing infection rates, increasing antimicrobial resistance and the extremely scarce treatment choices currently available.”

Health officials are particularly alarmed about the rise in treatment-resistant strains. The World Health Organization has classified it as a "high-priority threat". Recent surveillance showed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Treatment Options Secure Clearance

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to major issues, including infertility. Researchers anticipate that focused deployment of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, gained clearance in concurrent days. This treatment, which is also used to treat urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to develop it.

“This milestone marks a major breakthrough in the management of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Research Study Data and Global Access

As per results detailed in a prominent scientific publication, the new drug successfully treated the vast majority of uncomplicated infections. This establishes an comparable level with the existing first-line therapy, which uses two antibiotics. The trial enrolled hundreds of volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the authority to make available and distribute the drug in numerous developing nations.

Medical professionals treating patients have shared positive views. Access to a one-pill regimen such as this is described as a "game-changer" for managing the epidemic. This is considered crucial to reduce the burden of the disease for patients and to halt the transmission of highly drug-resistant gonorrhoea worldwide.